A tolerability and efficacy study of the angiogenesis inhibitor bevacizumab in combination With 5-fluorouracil, oxaliplatin, and external beam radiation therapy followed by gemcitabine and bevacizumab for locally advanced pancreatic cancer.

Trial Profile

A tolerability and efficacy study of the angiogenesis inhibitor bevacizumab in combination With 5-fluorouracil, oxaliplatin, and external beam radiation therapy followed by gemcitabine and bevacizumab for locally advanced pancreatic cancer.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 14 Oct 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Fluorouracil (Primary) ; Gemcitabine (Primary) ; Oxaliplatin (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 18 Aug 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 18 Aug 2009 Planned end date (1 Jul 2009) added as reported by ClinicalTrials.gov..
    • 25 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top